Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Effective vaccines to prevent Haemophilus influenzae type b (Hib) disease, introduced in the United States and most other countries, have resulted in a dramatic decrease in the incidence of infections caused by this organism. However, mortality and morbidity from Hib infection remain a problem worldwide, primarily in developing countries. Occasional cases of invasive disease caused by non–type b organisms continue to occur but are infrequent. Nontypeable members of the species are an important cause of otitis media, sinusitis, and chronic bronchitis.
Haemophilus influenzae is a fastidious, gram-negative, pleomorphic coccobacillus that requires factor X (hematin) and factor V (phosphopyridine nucleotide) for growth. Some H. influenzae isolates are surrounded by a polysaccharide capsule and can be serotyped into 1 of 6 antigenically and biochemically distinct types designated a, b, c, d, e, and f.
Before the advent of an effective Hib conjugate vaccine in 1988, H. influenzae type b was a major cause of serious disease among children. There was a striking age distribution of cases, with >90% in children <5 yr old and the majority in children <2 yr old. The annual attack rate of invasive disease was 64-129 cases per 100,000 children <5 yr old. Invasive disease caused by other capsular serotypes has been much less frequent but continues to occur. The incidence of invasive disease caused by type b and non–type b serotypes has been estimated at approximately 0.08 and 1.02 cases, respectively, per 100,000 children <5 yr old per year in the United States. Nonencapsulated (nontypeable) H. influenzae strains also occasionally cause invasive disease, especially in neonates, immunocompromised children, and children in developing countries. The estimated rate of invasive disease caused by nontypeable H. influenzae in the United States is 1.88 per 100,000 children <5 yr old per year. Nontypeable isolates are common etiologic agents in otitis media, sinusitis, and chronic bronchitis.
Humans are the only natural hosts for H. influenzae, which is part of the normal respiratory flora in 60–90% of healthy children. Most isolates are nontypeable. Before the advent of conjugate vaccine immunization, H. influenzae type b could be isolated from the pharynx of 2–5% of healthy preschool and school-age children, with lower rates among infants and adults. Asymptomatic colonization with Hib occurs at a much lower rate in immunized populations.
The continued circulation of the type b organism despite current vaccine coverage levels suggests that elimination of Hib disease may be a formidable task. The few cases of Hib invasive disease in the United States now occur in both unvaccinated and fully vaccinated children. Approximately 50% of cases occur in young infants who are too young to have received a complete primary vaccine series. Among the cases in patients who are old enough to have received a complete vaccine series, the majority are underimmunized. To highlight this point, during a shortage of Hib vaccine, invasive disease developed in 5 children in Minnesota, all of whom were incompletely immunized. Continued efforts are necessary to provide currently available Hib conjugate vaccines to children in developing countries, where affordability remains an important issue.
In the prevaccine era, certain groups and individuals had an increased incidence of invasive Hib disease, including Alaskan Natives, American Indians (Apache, Navajo), and African Americans. Persons with certain chronic medical conditions were also known to be at increased risk for invasive disease, including those with sickle cell disease, asplenia, congenital and acquired immunodeficiencies, and malignancies. Unvaccinated infants with invasive Hib infection are also at increased risk for recurrence, reflecting that they typically do not develop a protective immune response to H . influenzae.
Socioeconomic risk factors for invasive Hib disease include childcare outside the home, the presence of siblings of elementary school age or younger, short duration of breastfeeding, and parental smoking. A history of otitis media is associated with an increased risk for invasive disease. Much less is known about the epidemiology of invasive disease caused by non–type b strains, and it is not clear whether the epidemiologic features of Hib disease apply to disease caused by non-Hib isolates.
Among age-susceptible household contacts who have been exposed to a case of invasive Hib disease, there is increased risk for secondary cases of invasive disease in the 1st 30 days, especially in susceptible children <24 mo old. Whether a similar increased risk occurs for contacts of individuals with non-Hib disease is unknown.
The mode of transmission is usually direct contact or inhalation of respiratory tract droplets containing H. influenzae. The incubation period for invasive disease is variable, and the exact period of communicability is unknown. Most children with invasive Hib disease are colonized in the nasopharynx before initiation of antimicrobial therapy; 25–40% may remain colonized during the 1st 24 hr of therapy.
With the decline of disease caused by type b organisms, disease caused by other serotypes (a, c-f) and nontypeable organisms has been recognized more clearly. There is no evidence that these non–type b infections have increased in frequency. However, clusters of type a and, less often, type f and type e infections have occurred. Data from Israel suggest that nontypeable H. influenzae is the most common case of invasive H. influenzae disease in that country.
The pathogenesis of Hib disease begins with adherence to respiratory epithelium and colonization of the nasopharynx, which is mediated by pilus and nonpilus adherence factors. The mechanism of entry into the intravascular compartment is unclear but appears to be influenced by cytotoxic factors. Once in the bloodstream, H. influenzae type b, and perhaps other encapsulated strains, resist intravascular clearance mechanisms at least in part because of a polysaccharide capsule. In the case of Hib, the magnitude and duration of bacteremia influence the likelihood of dissemination of bacteria to sites such as the meninges and joints.
Noninvasive H. influenzae infections such as otitis media, sinusitis, and bronchitis are usually caused by nontypeable strains. These organisms gain access to sites such as the middle ear and sinus cavities by direct extension from the nasopharynx. Factors facilitating spread from the pharynx include eustachian tube dysfunction and antecedent viral infections of the upper respiratory tract.
Most H. influenzae isolates are susceptible to ampicillin or amoxicillin, but about one-third produce a β-lactamase and are therefore resistant to these antibiotics. β-Lactamase–negative ampicillin-resistant isolates have been identified and manifest resistance by production of a β-lactam–insensitive cell wall synthesis enzyme called PBP3.
Amoxicillin-clavulanate is uniformly active against H. influenzae clinical isolates except for the rare β-lactamase–negative ampicillin-resistant isolates. Among macrolides, azithromycin has in vitro activity against a high percentage of H. influenzae isolates; in contrast, the activity of erythromycin and clarithromycin against H. influenzae clinical isolates is poor. H. influenzae resistance to third-generation cephalosporins has not been documented. Resistance to trimethoprim-sulfamethoxazole (TMP-SMX) is infrequent (approximately 10%), and resistance to quinolones is believed to be rare.
In the prevaccine era, the most important known element of host defense was antibody directed against the type b capsular polysaccharide polyribosylribitol phosphate ( PRP ). Anti-PRP antibody is acquired in an age-related fashion and facilitates clearance of H. influenzae type b from blood, in part related to opsonic activity. Antibodies directed against antigens such as outer membrane proteins or lipopolysaccharide (LPS) may also have a role in opsonization. Both the classical and alternative complement pathways are important in defense against Hib.
Before the introduction of vaccination, protection from Hib infection was presumed to correlate with the concentration of circulating anti-PRP antibody at the time of exposure. A serum antibody concentration of 0.15-1.0 µg/mL was considered protective against invasive infection. Unimmunized infants >6 mo old and young children usually lacked an anti-PRP antibody concentration of this magnitude and were susceptible to disease after encountering Hib. This lack of antibody in infants and young children may have reflected a maturational delay in the immunologic response to thymus-independent type 2 antigens such as unconjugated PRP, presumably explaining the high incidence of type b infections in infants and young children in the prevaccine era.
The conjugate vaccines act as thymus-dependent antigens and elicit serum antibody responses in infants and young children ( Table 221.1 ). These vaccines are believed to prime memory antibody responses on subsequent encounters with PRP. The concentration of circulating anti-PRP antibody in a child primed by a conjugate vaccine may not correlate precisely with protection, presumably because a memory response may occur rapidly on exposure to PRP and provide protection.
VACCINE | TRADE NAME | COMPONENTS | MANUFACTURER |
---|---|---|---|
PRP-T | ActHib | PRP conjugated to tetanus toxoid | Sanofi |
PRP-T | Hibrix | PRP conjugated to tetanus toxoid | GlaxoSmithKline Biologicals |
PRP-OMP | PedvaxHIB | PRP conjugated to OMP | Merck |
PRP-T/DTaP-IPV | Pentacel | PRP-T + DTaP-IPV vaccines | Sanofi Pasteur |
Much less is known about immunity to other H. influenzae serotypes or to nontypeable isolates. For nontypeable isolates, evidence suggests that antibodies directed against 1 or more outer membrane proteins are bactericidal and protect against experimental challenge. A variety of antigens have been evaluated in an attempt to identify vaccine candidates for nontypeable H. influenzae, including outer membrane proteins (P1, P2, P4, P5, P6, D15, and Tbp A/B), LPS, various adhesins, and lipoprotein D.
Presumptive identification of H. influenzae is established by direct examination of the collected specimen after staining with Gram reagents. Because of its small size, pleomorphism, and occasional poor uptake of stain, as well as the tendency for proteinaceous fluids to have a red background, H. influenzae is sometimes difficult to visualize. Furthermore, given that identification of microorganisms on smear by either technique requires at least 10 5 bacteria/mL, failure to visualize them does not preclude their presence.
Culture of H. influenzae requires prompt transport and processing of specimens because the organism is fastidious. Specimens should not be exposed to drying or temperature extremes. Primary isolation of H. influenzae can be accomplished on chocolate agar or on blood agar plates using the staphylococcus streak technique.
Serotyping of H. influenzae is accomplished by slide agglutination with type-specific antisera. Accurate serotyping is essential to monitor progress toward elimination of type b invasive disease. Timely reporting of cases to public health authorities should be ensured.
The initial antibiotic therapy of invasive infections possibly caused by H. influenzae should be a parenterally administered antimicrobial agent effective in sterilizing all foci of infection and effective against ampicillin-resistant strains, usually an extended-spectrum cephalosporin such as ceftriaxone. These antibiotics have achieved popularity because of their relative lack of serious adverse effects and ease of administration. After the antimicrobial susceptibility of the isolate has been determined, an appropriate agent can be selected to complete the therapy. Ampicillin remains the drug of choice for the therapy of infections caused by susceptible isolates. If the isolate is resistant to ampicillin, ceftriaxone can be administered once daily in selected circumstances for outpatient therapy.
Oral antimicrobial agents are sometimes used to complete a course of therapy initiated by the parenteral route and are typically initial therapy for noninvasive infections such as otitis media and sinusitis. If the organism is susceptible, amoxicillin is the drug of choice. An oral second- or third-generation cephalosporin or amoxicillin-clavulanate may be used when the isolate is resistant to ampicillin.
In the prevaccine era, meningitis accounted for more than half of all cases of invasive H. influenzae disease. Clinically, meningitis caused by H. influenzae type b cannot be differentiated from meningitis caused by Neisseria meningitidis or Streptococcus pneumoniae (see Chapter 621.1 ). It may be complicated by other foci of infection such as the lungs, joints, bones, and pericardium.
Antimicrobial therapy should be administered intravenously for 7-14 days for uncomplicated cases. Ceftriaxone, and ampicillin cross the blood-brain barrier during acute inflammation in concentrations adequate to treat H. influenzae meningitis. Intramuscular therapy with ceftriaxone may be an alternative in patients with normal organ perfusion.
The prognosis of Hib meningitis depends on the age at presentation, duration of illness before appropriate antimicrobial therapy, cerebrospinal fluid (CSF) capsular polysaccharide concentration, and rapidity with which organisms are cleared from CSF, blood, and urine. Clinically manifested inappropriate secretion of antidiuretic hormone and evidence of focal neurologic deficits at presentation are poor prognostic features. Approximately 6% of patients with Hib meningitis are left with some hearing impairment, probably because of inflammation of the cochlea and the labyrinth. Dexamethasone (0.6 mg/kg/day divided every 6 hr for 2 days), particularly when given shortly before or concurrent with the initiation of antimicrobial therapy, decreases the incidence of hearing loss. Major neurologic sequelae of Hib meningitis include behavior problems, language disorders, impaired vision, mental retardation, motor abnormalities, ataxia, seizures, and hydrocephalus.
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here